VIVUS Inc (VVUS.OQ)
14.99USD
1 Aug 2013
$0.18 (+1.22%)
$14.81
$14.92
$15.07
$14.89
562,818
604,951
$24.86
$9.86
About
Overall
| Beta: | 1.31 |
| Market Cap (Mil.): | $1,493.81 |
| Shares Outstanding (Mil.): | 100.80 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VVUS.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -1.74 | -- | -- |
| ROI: | -69.73 | 19.48 | 18.76 |
| ROE: | -69.73 | 20.17 | 19.59 |
First Manhattan's point man on Vivus: Doctor and Buffett disciple
NEW YORK - When Dr. Sam Colin was an intern at the Yale School of Medicine, he often gave up the chance to catch a few minutes of sleep between shifts to read the latest investment insights from Warren Buffett.
First Manhattan's point man on Vivus: Doctor and Buffett disciple
NEW YORK, July 19 - When Dr. Sam Colin was an intern at the Yale School of Medicine, he often gave up the chance to catch a few minutes of sleep between shifts to read the latest investment insights from Warren Buffett.
Market Chatter-Corporate finance press digest
July 19 - The following corporate finance-related stories were reported by media on Friday:
Vivus set to give First Manhattan board majority -source
NEW YORK - Obesity drugmaker Vivus Inc is close to reaching a settlement with First Manhattan Co, giving the dissident investor a majority of the company board, a source familiar with the matter told Reuters on Thursday evening.
UPDATE 3-Vivus gives First Manhattan board majority, Zook to be CEO
* First Manhattan was pushing to replace entire Vivus board
Vivus vote delayed as company talks with shareholder-sources
NEW YORK - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.
UPDATE 1-Vivus vote delayed as company talks with shareholder-sources
NEW YORK, July 18 - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.
Vivus vote delayed as company negotiates with First Manhattan-sources
NEW YORK, July 18 - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.
Vivus says FMC rejects offer to settle proxy fight
- Obesity drug maker Vivus Inc, embroiled in a bitter proxy war with its top shareholder First Manhattan Co, said on Wednesday that FMC had rejected an offer to give the sides equal representation on the board.
UPDATE 2-Vivus says FMC rejects offer to settle proxy fight
July 17 - Obesity drug maker Vivus Inc, embroiled in a bitter proxy war with its top shareholder First Manhattan Co, said on Wednesday that FMC had rejected an offer to give the sides equal representation on the board.
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,605 | +25.00 |
| Eisai Co., Ltd (4523.T) | ¥4,215 | +50.00 |
| Novo Nordisk A/S (NOVOb.CO) | kr.975.00 | +27.00 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Eli Lilly & Co. (LLY.N) | $53.50 | +0.39 |
| Warner Chilcott Plc (WCRX.OQ) | $21.60 | +0.29 |
| Arena Pharmaceuticals, Inc. (ARNA.OQ) | $6.87 | -0.08 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

